Moxifloxacin monotherapy versus combination therapy in patients with severe community-acquired pneumonia evoked ARDS.
Tim RahmelSven AsmussenJan KarlikJörg SteinmannMichael AdamzikJürgen PetersPublished in: BMC anesthesiology (2017)
In CAP evoked ARDS, moxifloxacin monotherapy and moxifloxacin combination therapy was not different to a betalactam based antibiotic regimen with respect to 30-day mortality, and temporarily increased markers of liver cell integrity had no apparent clinical impact. Thus, in contrast to the current S3 guidelines, moxifloxacin may also be safe and effective even in patients with severe CAP evoked ARDS while providing coverage of an extended spectrum of severe CAP evoking bacteria. However, further prospective studies are needed for definite recommendations.
Keyphrases
- combination therapy
- acute respiratory distress syndrome
- extracorporeal membrane oxygenation
- community acquired pneumonia
- mechanical ventilation
- early onset
- clinical practice
- magnetic resonance
- single cell
- cell therapy
- randomized controlled trial
- magnetic resonance imaging
- type diabetes
- drug induced
- cardiovascular events
- clinical trial
- computed tomography
- mesenchymal stem cells
- study protocol
- health insurance